Trial Profile
A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination With Backbone Treatments for Subjects With Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Pembrolizumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms KEYNOTE-023
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 07 Oct 2020 Status changed from completed to discontinued.
- 26 Mar 2020 Status changed from active, no longer recruiting to completed.
- 21 Nov 2019 Planned End Date changed from 4 Feb 2020 to 24 Feb 2020.